vs
Bloomin' Brands, Inc.（BLMN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Bloomin' Brands, Inc.的季度营收约是Revvity的1.3倍（$975.2M vs $772.1M），Revvity净利率更高（12.7% vs -1.4%，领先14.1%），Revvity同比增速更快（5.9% vs 0.3%），Revvity自由现金流更多（$161.8M vs $63.7M），过去两年Revvity的营收复合增速更高（9.0% vs -4.5%）
Bloomin' Brands, Inc.是一家餐饮控股集团，1988年成立，总部位于美国佛罗里达州坦帕市，旗下拥有多个美式休闲餐饮连锁品牌，是北美休闲餐饮领域颇具规模的企业之一。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BLMN vs RVTY — 直观对比
营收规模更大
BLMN
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出5.5%
0.3%
净利率更高
RVTY
高出14.1%
-1.4%
自由现金流更多
RVTY
多$98.1M
$63.7M
两年增速更快
RVTY
近两年复合增速
-4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $975.2M | $772.1M |
| 净利润 | $-13.5M | $98.4M |
| 毛利率 | 70.2% | — |
| 营业利润率 | -1.4% | 14.5% |
| 净利率 | -1.4% | 12.7% |
| 营收同比 | 0.3% | 5.9% |
| 净利润同比 | 83.0% | 3.9% |
| 每股收益（稀释后） | $-0.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLMNRVTY
| Q4 25 | $975.2M | $772.1M | ||
| Q3 25 | $928.8M | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $972.0M | $729.4M | ||
| Q3 24 | $910.0M | $684.0M | ||
| Q2 24 | $999.4M | $691.7M | ||
| Q1 24 | $1.1B | $649.9M |
净利润BLMNRVTY
| Q4 25 | $-13.5M | $98.4M | ||
| Q3 25 | $-45.9M | $46.7M | ||
| Q2 25 | $25.4M | $53.9M | ||
| Q1 25 | $42.2M | $42.2M | ||
| Q4 24 | $-79.5M | $94.6M | ||
| Q3 24 | $6.9M | $94.4M | ||
| Q2 24 | $28.4M | $55.4M | ||
| Q1 24 | $-83.9M | $26.0M |
毛利率BLMNRVTY
| Q4 25 | 70.2% | — | ||
| Q3 25 | 70.4% | 53.6% | ||
| Q2 25 | 70.2% | 54.5% | ||
| Q1 25 | 70.1% | 56.5% | ||
| Q4 24 | 71.6% | — | ||
| Q3 24 | 71.3% | 56.3% | ||
| Q2 24 | 70.5% | 55.7% | ||
| Q1 24 | 70.5% | 54.6% |
营业利润率BLMNRVTY
| Q4 25 | -1.4% | 14.5% | ||
| Q3 25 | -3.9% | 11.7% | ||
| Q2 25 | 3.0% | 12.6% | ||
| Q1 25 | 5.5% | 10.9% | ||
| Q4 24 | 1.7% | 16.3% | ||
| Q3 24 | 0.9% | 14.3% | ||
| Q2 24 | 4.4% | 12.4% | ||
| Q1 24 | 6.6% | 6.8% |
净利率BLMNRVTY
| Q4 25 | -1.4% | 12.7% | ||
| Q3 25 | -4.9% | 6.7% | ||
| Q2 25 | 2.5% | 7.5% | ||
| Q1 25 | 4.0% | 6.4% | ||
| Q4 24 | -8.2% | 13.0% | ||
| Q3 24 | 0.8% | 13.8% | ||
| Q2 24 | 2.8% | 8.0% | ||
| Q1 24 | -7.8% | 4.0% |
每股收益（稀释后）BLMNRVTY
| Q4 25 | $-0.16 | $0.86 | ||
| Q3 25 | $-0.54 | $0.40 | ||
| Q2 25 | $0.30 | $0.46 | ||
| Q1 25 | $0.50 | $0.35 | ||
| Q4 24 | $-0.93 | $0.77 | ||
| Q3 24 | $0.08 | $0.77 | ||
| Q2 24 | $0.32 | $0.45 | ||
| Q1 24 | $-0.96 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $59.5M | $919.9M |
| 总债务越低越好 | $787.4M | — |
| 股东权益账面价值 | $333.6M | $7.3B |
| 总资产 | $3.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.36× | — |
8季度趋势，按日历期对齐
现金及短期投资BLMNRVTY
| Q4 25 | $59.5M | $919.9M | ||
| Q3 25 | $66.5M | $931.4M | ||
| Q2 25 | $50.3M | $991.8M | ||
| Q1 25 | $57.7M | $1.1B | ||
| Q4 24 | $70.1M | $1.2B | ||
| Q3 24 | $83.6M | $1.2B | ||
| Q2 24 | $117.9M | $2.0B | ||
| Q1 24 | $131.7M | $1.7B |
总债务BLMNRVTY
| Q4 25 | $787.4M | — | ||
| Q3 25 | $962.2M | — | ||
| Q2 25 | $917.1M | — | ||
| Q1 25 | $917.6M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $951.8M | — |
股东权益BLMNRVTY
| Q4 25 | $333.6M | $7.3B | ||
| Q3 25 | $344.1M | $7.4B | ||
| Q2 25 | $397.2M | $7.6B | ||
| Q1 25 | $380.6M | $7.6B | ||
| Q4 24 | $135.5M | $7.7B | ||
| Q3 24 | $242.1M | $7.9B | ||
| Q2 24 | $286.8M | $7.9B | ||
| Q1 24 | $302.7M | $7.8B |
总资产BLMNRVTY
| Q4 25 | $3.2B | $12.2B | ||
| Q3 25 | $3.3B | $12.1B | ||
| Q2 25 | $3.3B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
负债/权益比BLMNRVTY
| Q4 25 | 2.36× | — | ||
| Q3 25 | 2.80× | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | 2.41× | — | ||
| Q4 24 | 7.58× | — | ||
| Q3 24 | 4.51× | — | ||
| Q2 24 | 3.49× | — | ||
| Q1 24 | 3.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $119.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $63.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.5% | 21.0% |
| 资本支出强度资本支出/营收 | 5.7% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $96.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BLMNRVTY
| Q4 25 | $119.1M | $182.0M | ||
| Q3 25 | $34.4M | $138.5M | ||
| Q2 25 | $49.7M | $134.3M | ||
| Q1 25 | $73.5M | $128.2M | ||
| Q4 24 | $119.8M | $174.2M | ||
| Q3 24 | $-7.8M | $147.9M | ||
| Q2 24 | $42.4M | $158.6M | ||
| Q1 24 | $73.8M | $147.6M |
自由现金流BLMNRVTY
| Q4 25 | $63.7M | $161.8M | ||
| Q3 25 | $-5.7M | $120.0M | ||
| Q2 25 | $11.1M | $115.5M | ||
| Q1 25 | $27.7M | $112.2M | ||
| Q4 24 | $66.7M | $149.8M | ||
| Q3 24 | $-67.3M | $125.6M | ||
| Q2 24 | $-12.1M | $136.6M | ||
| Q1 24 | $20.0M | $129.7M |
自由现金流率BLMNRVTY
| Q4 25 | 6.5% | 21.0% | ||
| Q3 25 | -0.6% | 17.2% | ||
| Q2 25 | 1.1% | 16.0% | ||
| Q1 25 | 2.6% | 16.9% | ||
| Q4 24 | 6.9% | 20.5% | ||
| Q3 24 | -7.4% | 18.4% | ||
| Q2 24 | -1.2% | 19.7% | ||
| Q1 24 | 1.9% | 20.0% |
资本支出强度BLMNRVTY
| Q4 25 | 5.7% | 2.6% | ||
| Q3 25 | 4.3% | 2.6% | ||
| Q2 25 | 3.8% | 2.6% | ||
| Q1 25 | 4.4% | 2.4% | ||
| Q4 24 | 5.5% | 3.4% | ||
| Q3 24 | 6.5% | 3.3% | ||
| Q2 24 | 5.5% | 3.2% | ||
| Q1 24 | 5.0% | 2.7% |
现金转化率BLMNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 1.95× | 2.49× | ||
| Q1 25 | 1.74× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | -1.13× | 1.57× | ||
| Q2 24 | 1.49× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLMN
| Food And Beverage | $958.0M | 98% |
| Franchiseand Other Revenue | $17.2M | 2% |
| International Franchise Segment | $7.8M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
